I believe you are incorrect regarding finasteride/dutasteride not affecting neurosteroids. In rats neurosteroid levels are definitively impacted. There’s also rather strong evidence in humans. Please see Melcangi R.C., Santi D., Spezzano R., Grimoldi M., Tabacchi T., Fusco M.L. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229–235.
Also Motofei I.G., Rowland D.L., Tampa M., Sarbu M.I., Mitran M.I., Mitran C.I. Finasteride and androgenic alopecia; from therapeutic options to medical implications. J Dermatolog Treat.
The latter study showed decreased P4, DHP, THP, as well as reductions in CSF DHT and T.
Alteration of neurosteroids fits with the not uncommon side effects of depression, sexual dysfunction, and apathy associated with 5-AR blockade.
5-AR blockade also decreases dopaminergic transmission in the brain and inhibits neurogenesis in the hippocampus in rat models.
Please see:
The post-finasteride syndrome: possible etiological mechanisms and symptoms. Leliefeld, et al. 2023.
The above review has an excellent explanation regarding the lipophilic nature of dutasteride/finasteride. Easy access across the blood barrier and inhibition of 5-AR1/AR2 which are both present in the brain. Also provides references regarding alteration of neurosteroids in humans and how these alterations can remain permanent despite d/c of the drug in both humans and rodents.
Metabolically we have evidence for insulin resistance, increased adiposity, bone loss, muscle loss, and reduced clearance of glucocorticoids. I can provide additional references at your preference.
Majority of the above are studies looking at PFS (post finasteride syndrome) which I fully admit the exact etiology is unknown. Nonetheless the studies provide ample evidence of the deleterious effects of 5-AR blockade with the potential for some of these effects to be permanent.
On the contrary, I’m not aware of any evidence that these drugs prolong human longevity or health span and the reduction in Gleason 6 prostate CA is of questionable clinical benefit given the standard of care for this type of prostate cancer is simply active surveillance.